Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma.

Bonfiglio, Ferdinando; Bruscaggin, Alessio; Guidetti, Francesca; Terzi di Bergamo, Lodovico; Faderl, Martin Richard; Spina, Valeria; Condoluci, Adalgisa; Bonomini, Luisella; Forestieri, Gabriela; Koch, Ricardo; Piffaretti, Deborah; Pini, Katia; Pirosa, Maria C; Cittone, Micol Giulia; Arribas, Alberto; Lucioni, Marco; Ghilardi, Guido; Wu, Wei; Arcaini, Luca; Baptista, Maria Joao; ... (2022). Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. Blood, 139(5), pp. 732-747. American Society of Hematology 10.1182/blood.2021012386

[img]
Preview
Text
blood.2021012386.pdf - Accepted Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, essential regulatory pathways and surrounding microenvironments are diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups and their underlying genomic abnormalities, pathway signatures and microenvironment compositions to uncover biomarkers and therapeutic vulnerabilities. We studied 303 SMZL spleen samples collected through the IELSG46 multicenter, international study (NCT02945319) by using a multiplatform approach. We carried out genetic and phenotypic analyses, defined self-organized signatures, validated the findings in independent primary tumor meta-data and in genetically modified mouse models, and determined correlations with outcome data. We identified two prominent genetic clusters in SMZL, termed NNK (58% of cases, harboring NF-κB, NOTCH and KLF2 modules) and DMT (32% of cases, with DNA-damage response, MAPK and TLR modules). Genetic aberrations in multiple genes as well as cytogenetic and immunogenetic features distinguished NNK- from DMT-SMZLs. These genetic clusters not only have distinct underpinning biology, as judged by differences in gene-expression signatures, but also different outcome, with inferior survival in NNK-SMZLs. Digital cytometry and in situ profiling segregated two basic types of SMZL immune microenvironments termed immune-suppressive SMZL (50% of cases, associated with inflammatory cells and immune checkpoint activation) and immune-silent SMZL (50% of cases, associated with an immune-excluded phenotype) with distinct mutational and clinical connotations. In summary, we propose a nosology of SMZL that can implement its classification and also aid in the development of rationally targeted treatments.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Novak, Urban

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0006-4971

Publisher:

American Society of Hematology

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

01 Dec 2021 14:34

Last Modified:

05 Dec 2022 15:54

Publisher DOI:

10.1182/blood.2021012386

PubMed ID:

34653238

BORIS DOI:

10.48350/160882

URI:

https://boris.unibe.ch/id/eprint/160882

Actions (login required)

Edit item Edit item
Provide Feedback